Liangyi Zhang is a seasoned leader with 15 years of experience in the Chemistry, Manufacturing, and Controls (CMC) of biologics, antibody-drug conjugates (ADCs), and CAR-T cell therapies. He brings a strong background in both technical and organizational leadership, with a proven track record in analytical development and pharmaceutical development.

Liangyi has demonstrated exceptional leadership in building and guiding analytical and pharmaceutical development functions within CMC to meet strategic business objectives. Under his direction, he has successfully advanced more than 20 programs through early-stage development and led three programs to late-stage development and commercialization.

Liangyi’s expertise in the CMC development of ADCs is extensive, having played a key role as an analytical team leader in guiding analytical activities from Investigational New Drug (IND) application through to the successful Biologics License Application (BLA) approval of the first PBD-based ADC, Zynlonta®, during his time at ADC Therapeutics.